Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Wânia Cristina da SilvaVânia Eloisa de AraújoEllias Magalhães E Abreu LimaJéssica Barreto Ribeiro Dos SantosMichael Ruberson Ribeiro da SilvaPaulo Henrique Ribeiro Fernandes AlmeidaFrancisco de Assis AcurcioBrian B GodmanAmanj Baker KurdiMariângela Leal CherchigliaEli Iola Gurgel AndradePublished in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2019)
The results pointed to an advantage in favor of bevacizumab for OS, PFS, PPS, and metastasectomy. Although this advantage may be considered clinically modest, bevacizumab represents a hope for increased survival and a chance of metastasectomy for patients with mCRC. However, there are serious adverse events associated with its use, especially severe hypertension and gastrointestinal perforation, that need to be considered.